Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.
Fiche publication
Date publication
août 2023
Journal
Frontiers in medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle, Pr DE CARVALHO BITTENCOURT Marcelo, Pr DECOT Véronique, Dr POCHON Cécile, Dr REPPEL Loïc, Dr GAUTHIER Michaël
Tous les auteurs :
Pochon C, Laroye C, Kimmoun A, Reppel L, Dhuyser A, Rousseau H, Gauthier M, Petitpain N, Chabot JF, Valentin S, de Carvalho Bittencourt M, Peres M, Aarnink A, Decot V, Bensoussan D, Gibot S
Lien Pubmed
Résumé
The COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by the SARS-CoV-2 infection through pro-angiogenic effects, lung epithelial cell protection, and immunomodulation.
Mots clés
ARDS, COVID-19, intensive care, mesenchymal stromal cells, oxygenation
Référence
Front Med (Lausanne). 2023 08 29;10:1224865